Edetic Acid
CAS 60-00-4
Edetic Acid (CAS 60-00-4) is a Phase 3 pharmaceutical compound with 7 bioactivity targets and 597 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 18842.105263157893 nM | 95 | - |
| - | IC50 | 26729.17238095238 nM | 20 | - |
| - | MIC | 168750 nM | 4 | - |
| - | Potency | 7356.325 nM | 4 | - |
| - | MIC | 0.25 ug.mL-1 | 3 | - |
| - | EC50 | 14000 nM | 2 | - |
| - | EC50 | 0.000034 ug.mL-1 | 1 | - |
| - | IC50 | 44.11 ug.mL-1 | 1 | - |
| Angiotensin-converting enzyme Enzyme |
IC50 | 4.85 | - | Homo sapiens |
| Ceramide glucosyltransferase Enzyme |
- | - | - | Homo sapiens |
| Beta-lactamase Enzyme |
IC50 | 4.55 | - | Pseudomonas aeruginosa |
| Beta-lactamase VIM-1; Class B carbapenemase VIM-1; Metallo-beta-lactamase; Metallo-beta-lactamase VIM-1; Metallobeta-lactamase; VIM-1; VIM-1 metallo-beta lactamase; VIM-1 metallo-beta-lactamase; VIM-1 Unclassified |
IC50 | 5.03 | - | Pseudomonas aeruginosa |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B Enzyme |
IC50 | 4.13 | - | Crotalus adamanteus |
| Amyloid beta A4 protein Unclassified |
IC50 | 5.11 | - | Homo sapiens |
| Eyes absent homolog 2 Enzyme |
IC50 | 4.19 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Gastrointestinal toxicity | 91 | 419.067 | 10059024 |
| Pulmonary toxicity | 90 | 384.981 | 10061924 |
| Joint injury | 90 | 313.593 | 10060820 |
| Neoplasm malignant | 91 | 291.407 | 10028997 |
| Hepatotoxicity | 91 | 273.651 | 10019851 |
| C-reactive protein abnormal | 87 | 267.722 | 10068559 |
| Joint stiffness | 77 | 231.786 | 10023230 |
| Musculoskeletal pain | 91 | 216.119 | 10028391 |
| Therapy non-responder | 90 | 215.468 | 10051082 |
| Musculoskeletal stiffness | 91 | 158.575 | 10052904 |
| Treatment failure | 90 | 146.604 | 10066901 |
| Therapeutic product effect incomplete | 75 | 135.762 | 10082200 |
| Infection | 90 | 125.346 | 10021789 |
| Joint swelling | 90 | 113.174 | 10023232 |
| Pain in extremity | 94 | 112.483 | 10033425 |
| Arthropathy | 76 | 108.907 | 10003285 |
| Condition aggravated | 99 | 96.003 | 10010264 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| EDTA | 3755 | SU | MTHSPL |
| EDETIC ACID | 3755 | SU | MTHSPL |
| Edetic Acid | 3755 | SU | MTHSPL |
| edetic acid | 3755 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Edetic Acid used for in pharmaceutical contexts?
Edetic Acid (CAS 60-00-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Edetic Acid?
Edetic Acid has 597 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Gastrointestinal toxicity, Pulmonary toxicity, Joint injury, Neoplasm malignant, Hepatotoxicity. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Edetic Acid also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for EDTA with EU status "permitted".
What clinical phase is Edetic Acid in?
Edetic Acid is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Edetic Acid?
Edetic Acid has 15 bioactivity rows in this page query. Rendered target entries include Angiotensin-converting enzyme, Ceramide glucosyltransferase, Beta-lactamase, Beta-lactamase VIM-1; Class B carbapenemase VIM-1; Metallo-beta-lactamase; Metallo-beta-lactamase VIM-1; Metallobeta-lactamase; VIM-1; VIM-1 metallo-beta lactamase; VIM-1 metallo-beta-lactamase; VIM-1, cAMP-specific 3',5'-cyclic phosphodiesterase 4B.